ReviewCurrent urology reports2018
The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Review in Current urology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Prostate cancer risk and antioxidant biomarkers: the age-dependent reversal of bilirubin's role.BMC urology · 2025Article
- Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM).ESMO open · 2025Review
- Article
- Long-Term Exposure to Supraphysiological Levels of Testosterone Impacts Rat Submandibular Gland Proteome.International journal of molecular sciences · 2023Article
- Identifying the outcomes important to men with hypogonadism: A qualitative evidence synthesis.Andrology · 2022Review
- Testosterone Deficiency is Not Protective Against the Development of Adenocarcinoma of the Prostate in a Type 1 Diabetic Patient.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Molecular Mechanisms of Coffee on Prostate Cancer Prevention.BioMed research international · 2022Review
- Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.The journal of sexual medicine · 2021Article
- Hypogonadism and its treatment among prostate cancer survivors.International journal of impotence research · 2021Review
- Endocrinology of the Aging Prostate: Current Concepts.Frontiers in endocrinology · 2021Review
- Testosterone and prostate health: Have the paradigms truly shifted?Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe role of testosterone in the development of prostate cancer and the safety of testosterone therapy (TTh) after prostate cancer treatment, or in the setting of active surveillance, remains controversial. There are many concerns about using TTh in men, particularly those with a history of prostate cancer, ranging from a possible increased risk of cardiovascular disease to cancer progression or recurrence. With many prostate cancer patients living longer, and hypogonadism having significant morbidity, much care must go into the decision to treat. Here, we review the literature investigating the effects of testosterone on the prostate as well as the efficacy and safety of exogenous testosterone in men with a history of prostate cancer. RECENT
findingsThe improvement in quality of life with TTh is well studied and understood, while the argument for significantly increased risk of cancer or other adverse effects is much less robust. Neither increased rates of prostate cancer, cancer recurrence, or cardiovascular risk have been well established. In men with high-risk prostate cancer, evidence in the setting of TTh is very limited, and TTh should be used with caution. The fears of TTh causing or worsening prostate cancer do not appear to be well supported by available data. Though more studies are needed to definitively determine the safety of TTh in men with prostate cancer, consideration should be given to treatment of hypogonadal men with a history of CaP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.